Embecta Corp. EMBC

What this company does

Embecta Corp. markets a portfolio of products for diabetes management, including pen needles, syringes and safety injection devices. It estimates that its products are used by more than 30 million people in over 100 countries for insulin administration and diabetes management. As of September 30, 2025, it had approximately 1,850 regular employees globally, of which approximately 700 were in the United States. It operates three manufacturing sites, located in Ireland, the United States and China. As of September 30, 2025, it held about 655 patents in the United States and various foreign countries, along with about 45 patent applications pending worldwide, protecting its core injection business. On April 1, 2022, Embecta and Becton, Dickinson and Company entered into a Separation and Distribution Agreement. Under that agreement, Becton, Dickinson and Company agreed to spin off its diabetes care business into Embecta as a new, publicly traded company.

Written from the business description in Embecta Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 25 November 2025. Every sentence was checked against that document before publication.